Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... [Yahoo! Finance]
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: Yahoo! Finance
Total Operating Expenditure: $55.6 million in Q3 2024. Operating Expense Reduction: Expected reduction of approximately 25% in 2025 and over 30% in subsequent years. Revenue Projection: Combined U.S. peak revenue of $400 million for TCR T-cell and lete-cel. Authorized Treatment Centers (ATCs): 9 centers accepting patients, with 4 additional sites signed and 15 in active negotiations. Insurance Coverage: Over 67% of commercial lives covered for Tecelra. Patient Flow: Approximately 15 patients confirmed as double positive for Tecelra treatment. IGNYTE-ESO Trial Results: 42% response rate overall, with 6 complete responses. Median Duration of Response: Over a year for MRCLS and over 18 months for synovial sarcoma. Warning! GuruFocus has detected 4 Warning Signs with ADAP. Release Date: November 13, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Adaptimmune Therapeutics PLC ( NASDAQ:ADAP ) has announced a new
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at HC Wainwright from $4.00 to $3.50. They now have a "buy" rating on the stock.MarketBeat
- Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints [Yahoo! Finance]Yahoo! Finance
- Adaptimmune Reports Q3 2024 Financial and Business Updates [Yahoo! Finance]Yahoo! Finance
- Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - TechnavioPR Newswire
- Adaptimmune to Participate in Scientific and Medical Conferences this November and December [Yahoo! Finance]Yahoo! Finance
ADAP
Earnings
- 11/13/24 - Beat
ADAP
Sec Filings
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- 11/13/24 - Form 8-K
- ADAP's page on the SEC website